---
title: "CLDX.US (CLDX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CLDX.US/news.md"
symbol: "CLDX.US"
name: "CLDX.US"
parent: "https://longbridge.com/en/quote/CLDX.US.md"
datetime: "2026-05-20T08:16:44.509Z"
locales:
  - [en](https://longbridge.com/en/quote/CLDX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CLDX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CLDX.US/news.md)
---

# CLDX.US (CLDX.US) — Related News

### [12 Health Care Stocks Moving In Tuesday's After-Market Session](https://longbridge.com/en/news/286969790.md)
*2026-05-19T21:06:03.000Z*
> In Tuesday's after-market session, Co-Diagnostics shares surged 20.8% to $2.38, while Celldex Therapeutics rose 16.05% t

### [Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock](https://longbridge.com/en/news/285749494.md)
*2026-05-08T15:34:53.000Z*
> Barclays has raised its target price for Celldex Therapeutics (NASDAQ:CLDX) from $45.00 to $48.00, maintaining an "overw

### [12 Health Care Stocks Moving In Friday's Pre-Market Session](https://longbridge.com/en/news/285722413.md)
*2026-05-08T12:05:56.000Z*
> In Friday's pre-market session, Traws Pharma (NASDAQ:TRAW) shares surged 37% to $2.33, while Amylyx Pharmaceuticals (NAS

### [Celldex Therap | 8-K: FY2026 Q1 Revenue: USD 15 K](https://longbridge.com/en/news/285656957.md)
*2026-05-08T03:15:44.000Z*
### [Celldex Therap | 10-Q: FY2026 Q1 Revenue: USD 15 K](https://longbridge.com/en/news/285610017.md)
*2026-05-07T20:16:59.000Z*
### [Assessing Seagate Technology Holdings (STX) Valuation After Strong Recent Share Price Gains](https://longbridge.com/en/news/283584002.md)
*2026-04-22T02:04:32.000Z*
> Seagate Technology Holdings (STX) has experienced significant share price gains, with a 36.15% return over the past mont

### [Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade](https://longbridge.com/en/news/283378112.md)
*2026-04-20T15:32:25.000Z*
> Celldex Therapeutics (NASDAQ:CLDX) shares gapped up after Barclays upgraded the stock from underweight to overweight, ra

### [A Top Wall Street Analyst 'Can't Ignore' Celldex Stock (CLDX)](https://longbridge.com/en/news/283370239.md)
*2026-04-20T14:19:17.000Z*
> Celldex (CLDX) stock received a double upgrade from Barclays analyst Etzer Darout, raising its rating to Overweight and